Clinical and experimental effects of growth hormone secretagogues on various organ systems.
A new class of growth hormone (GH) secretagogues (GHS) has been developed. In rats, the GHS hexarelin exerts cardioprotective effects. In humans, GHS increase growth velocity in children with short stature/GH deficiency. In adults, a combined infusion of GH releasing peptide-2 and thyrotropin releasing hormone increases circulating concentrations of GH as well as that of insulin-like growth factor-I. In healthy volunteers, oral GHS administration reverses diet-induced catabolism, and in healthy obese men, oral GHS treatment increases fat-free mass. However, little is known about the possible direct effects of GHS and there are few long-term studies. Therefore, it is not yet possible to fully evaluate the use of GHS.
Svensson
J A
JA
Research Centre for Endocrinology and Metabolism, Sahlgrenska University Hospital, Göteborg, Sweden.
Bengtsson
B
B
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001823:Body Composition / Q000187:drug effects; D001921:Brain / Q000187:drug effects; D006128:Growth / Q000187:drug effects; D013007:Growth Hormone-Releasing Hormone; D006321:Heart / Q000187:drug effects; D019382:Human Growth Hormone / Q000378:metabolism*; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology; D013141:Spiro Compounds / Q000494:pharmacology
D001786:Blood Glucose; D007211:Indoles; D009842:Oligopeptides; D013141:Spiro Compounds; D019382:Human Growth Hormone; C041048:growth hormone releasing hexapeptide; D013007:Growth Hormone-Releasing Hormone; C094817:ibutamoren mesylate